Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Pfizer (NYSE:PFE) and maintained a $45 price target.
April 18, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald reaffirms an Overweight rating on Pfizer, with a $45 price target.
The reiteration of an Overweight rating and maintenance of a $45 price target by a reputable analyst firm like Cantor Fitzgerald could positively influence investor sentiment towards Pfizer in the short term. This endorsement reflects confidence in Pfizer's stock performance and potential for growth, likely encouraging investment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100